Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Au
Wing-Yan
WY
Tam
Sidney
S
Fong
Bonnie M
BM
Kwong
Yok-Lam
YL
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001151:Arsenic / Q000097:blood / Q000134:cerebrospinal fluid*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy*; D008297:Male; D008577:Meningeal Neoplasms / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000556:secondary*; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012008:Recurrence
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D001151:Arsenic; D000077237:Arsenic Trioxide